Drugs / Huachansu
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT02647125 | Sep 2015 → Sep 2022 | esophageal squamous cell carcinoma | Fudan University | Completed | Missed primary |
| Phase 2 | NCT01715532 | Jul 2012 → Jun 2016 | hepatocellular carcinoma | Fudan University | Unknown | Met primary |
| Phase 2 | NCT00837239 | Jun 2007 → Jul 2012 | malignant pancreatic neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05594927 Comparator | Dec 2022 → Aug 2025 overdue | hepatocellular carcinoma | Beijing Shenogen Biomedical Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Huachansu | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05594927 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Huachansu, a Chinese medicine derived from the dried skin glands of toad venom” PMID 37400162 ↗ Jul 2023 |
| Route | Intravenous | “A PICC is a tube that is inserted into a vein, either in your arm or under the collarbone, to make it easier to give you gemcitabine with or without HuaChanSu.” NCT00837239 ↗ |